Published in Eur J Endocrinol on August 01, 2001
Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? BMC Cancer (2002) 1.28
Recent advances in molecular biology of thyroid cancer and their clinical implications. Otolaryngol Clin North Am (2008) 1.19
Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J Clin Endocrinol Metab (2009) 1.06
Expression patterns of glucose transporter-1 gene and thyroid specific genes in human papillary thyroid carcinoma. Nucl Med Mol Imaging (2014) 0.91
Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene. BMC Cancer (2005) 0.90
Thyroid-specific transcription factors control Hex promoter activity. Nucleic Acids Res (2003) 0.86
Regulation and roles of bicarbonate transporters in cancer. Front Physiol (2014) 0.85
Pendrin is a novel in vivo downstream target gene of the TTF-1/Nkx-2.1 homeodomain transcription factor in differentiated thyroid cells. Mol Cell Biol (2005) 0.84
Expression of pendrin in benign and malignant human thyroid tissues. Br J Cancer (2005) 0.81
The Effect of Tanespimycin (17-AAG) on Radioiodine Accumulation in Sodium-Iodide Symporter Expressing Cells. Nucl Med Mol Imaging (2012) 0.78
Expression of PAX8 Target Genes in Papillary Thyroid Carcinoma. PLoS One (2016) 0.75
PDE5 Inhibitors-Loaded Nanovesicles: Physico-Chemical Properties and In Vitro Antiproliferative Activity. Nanomaterials (Basel) (2016) 0.75
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab (2006) 5.78
Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab (1986) 2.70
Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer (1998) 2.57
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol (1998) 2.55
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer (1999) 2.40
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet (2000) 2.31
Second primary malignancies in thyroid cancer patients. Br J Cancer (2003) 2.10
Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf) (1998) 1.99
Absence of activating mutations in the GnRH receptor gene in human pituitary gonadotroph adenomas. Eur J Endocrinol (1998) 1.99
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab (2005) 1.98
Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab (2000) 1.96
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab (2007) 1.93
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab (1999) 1.92
High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene (1997) 1.91
Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood (1998) 1.71
Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet (2001) 1.68
Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab (1999) 1.67
Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer (1985) 1.66
Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood (1996) 1.59
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract (2011) 1.59
Iodine-induced thyrotoxicosis in Kivu, Zaire. Lancet (1996) 1.57
Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol (2004) 1.52
The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer (2004) 1.52
Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol (1999) 1.51
Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab (2000) 1.49
Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities? Ann Oncol (1995) 1.49
Thyrotropin receptor mutations and thyroid hyperfunctioning adenomas ten years after their first discovery: unresolved questions. Thyroid (2003) 1.46
Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia. Br J Haematol (2000) 1.46
ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene (2011) 1.45
Detection of an activating mutation of the thyrotropin receptor in a case of an autonomously hyperfunctioning thyroid insular carcinoma. J Clin Endocrinol Metab (1997) 1.44
Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res (2000) 1.43
Presence of mutations in all three ras genes in human thyroid tumors. Oncogene (1990) 1.42
Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol (1999) 1.42
Elevation of CA 125 in patients with benign and malignant ascites. Cancer (1987) 1.42
Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol) (2010) 1.41
Functional and immunological relevance of the COOH-terminal extension of human chorionic gonadotropin beta: implications for the WHO birth control vaccine. FASEB J (1993) 1.41
Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res (1993) 1.41
Antiproteinuric effect of Losartan in patients with chronic renal diseases. Nephrol Dial Transplant (1997) 1.41
Heat-induced unfolding of neocarzinostatin, a small all-beta protein investigated by small-angle X-ray scattering. J Mol Biol (2001) 1.41
A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia. Haematologica (1999) 1.39
gsp mutations in human thyroid tumours. Oncogene (1991) 1.37
Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer (2011) 1.36
RET mutations in exons 13 and 14 of FMTC patients. Oncogene (1995) 1.35
Increased aggressiveness of thyroid cancer in patients with Graves' disease. J Clin Endocrinol Metab (1990) 1.31
Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res (2001) 1.30
Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer (2001) 1.30
External radiotherapy in thyroid cancers. Cancer (1985) 1.28
Insensitivity to anti-müllerian hormone due to a mutation in the human anti-müllerian hormone receptor. Nat Genet (1995) 1.27
Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. J Clin Endocrinol Metab (1997) 1.25
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer (1998) 1.23
An insertion in the human thyrotropin receptor critical for high affinity hormone binding. Science (1990) 1.21
The Kell blood group system: Kell and XK membrane proteins. Semin Hematol (2000) 1.20
Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab (2011) 1.20
Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer (2001) 1.19
Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs à Calcitonine. J Clin Endocrinol Metab (1998) 1.18
Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol (2010) 1.18
Bortezomib as an antitumor agent. Curr Pharm Biotechnol (2006) 1.17
Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine. Am J Hum Genet (1997) 1.16
Expression of pendrin and the Pendred syndrome (PDS) gene in human thyroid tissues. J Clin Endocrinol Metab (2000) 1.15
Patient-controlled analgesia in children and adolescents: a randomized, prospective comparison with intramuscular administration of morphine for postoperative analgesia. J Pediatr (1991) 1.15
Staging and prognosis in chronic myelogenous leukemia. Semin Hematol (1988) 1.15
Thyrotropin-luteinizing hormone/chorionic gonadotropin receptor extracellular domain chimeras as probes for thyrotropin receptor function. Proc Natl Acad Sci U S A (1991) 1.15
Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab (2012) 1.13
Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. J Clin Endocrinol Metab (1997) 1.13
Clinical experience with a human thyroid cell bioassay for thyroid-stimulating immunoglobulin. J Clin Endocrinol Metab (1984) 1.13
Thyroid carcinomas after irradiation for a first cancer during childhood. Arch Intern Med (2000) 1.13
Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms. Cancer Res (1992) 1.13
Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab (1997) 1.12
Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene (1988) 1.12
Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab (2005) 1.11
Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs Endocrines. J Clin Endocrinol Metab (2010) 1.11
High frequency of cancer in cold thyroid nodules occurring at young age. Acta Endocrinol (Copenh) (1989) 1.10
Expression of Na+/I- symporter and Pendred syndrome genes in trophoblast cells. J Clin Endocrinol Metab (2000) 1.10
Proteolytic processing of big endothelin-3 by the kell blood group protein. Blood (1999) 1.10
Radiation sensitivity of human lung cancer cell lines. Eur J Cancer Clin Oncol (1989) 1.10
Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology (2000) 1.10
Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab (2003) 1.10
Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab (1998) 1.08
Genetic heterogeneity in familial nonmedullary thyroid carcinoma: exclusion of linkage to RET, MNG1, and TCO in 56 families. NMTC Consortium. J Clin Endocrinol Metab (1999) 1.07
Na(+)/I(-) symporter and Pendred syndrome gene and protein expressions in human extra-thyroidal tissues. Eur J Endocrinol (2001) 1.07